WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS

WCN25-52 EPIDEMIOLOGY OF IMMUNOGLOBULIN A NEPHROPATHY (IgAN) AND OCCURRENCE OF PROTEINURIA IN CHINA: EVIDENCE FROM SYSTEMATIC REVIEW AND META-ANALYSIS

Saved in:

Bibliographic Details
Main Authors:	Zhaoxin Chen, Yilong Zhang, Wentian Lu, Jiaqi Kou, Jiaxi Zhu, Hema K. Gandhi, Sasikiran Nunna
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924025324
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-1268 End-Stage Kidney Disease (ESKD) and Chronic Kidney Disease (CKD) Progression among a Hispanic/Latino Population with Primary Immunoglobulin A Nephropathy (IgAN)
by: John Sim, et al.
Published: (2024-04-01)

Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review
by: Sarah N. Ali, et al.
Published: (2025-05-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-2352 Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN
by: Neeharik Mareedu, et al.
Published: (2024-04-01)

WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1664 Epidemiology, disease burden and treatment patterns for primary IgA nephropathy patients: A real-world data study in The Netherlands
by: Thom Lysen, et al.
Published: (2025-02-01)

Enteric-coated Mycophenolate Sodium plus hydroxychloroquine therApy versus hydroxychloroquine for the Remission of Proteinuria in IgA Nephropathy (EMSAR-IgAN trial): study protocol for a randomised trial
by: Lihua Wang, et al.
Published: (2025-04-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2025-02-01)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

Current status of clinical studies of IgA nephropathy with minimal proteinuria
by: SHI Yu-zhen, et al.
Published: (2020-01-01)

Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)

Serum Galactose-Deficient IgA1 Level Is Not Associated with Proteinuria in Children with IgA Nephropathy
by: M. Colleen Hastings, et al.
Published: (2012-01-01)

2bRAD-M reveals circulating microbiome in chronic antibody-mediated rejection (CAMR) and IgA nephropathy (IgAN) after kidney transplantation
by: Yan-Xin Tao, et al.
Published: (2025-07-01)

WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)
by: Lisa Kivman, et al.
Published: (2025-02-01)

WCN25-1084 INTERNATIONAL RISK-PREDICTION TOOL IN IgAN AND THE PROGNOSTIC IMPLICATIONS OF CRESCENTS
by: Beatriz Mendes, et al.
Published: (2025-02-01)

Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide
by: Christodoulos Keskinis, et al.
Published: (2025-04-01)

WCN25-4528 POST TRANSPLANT CRESCENTIC IgAN- FIRST CASE SERIES FROM INDIA
by: NITISH THAKUR, et al.
Published: (2025-02-01)

WCN25-2522 ORIGIN Extend: A Long-Term Extension Study of Atacicept in IgAN
by: Jonathan Barratt, et al.
Published: (2025-02-01)

The proteinuria selectivity index value predicts the remission of IgA nephropathy: a retrospective cohort study
by: Ryunosuke Mitsuno, et al.
Published: (2024-12-01)

Clinicopathological features and renal dysfunction risk factors of IgA nephropathy patients presenting with mild proteinuria
by: LIU Jie, et al.
Published: (2018-01-01)

Correlation of E1 Lesions and CD68 Count with Proteinuria and Clinical Outcome in IgA Nephropathy
by: Sistla Radha, et al.
Published: (2022-04-01)

Exploring the mechanism of proteinuria reduction by hydroxychloroquine in IgA nephropathy using network pharmacology and molecular mocking
by: Meiqi Lu, et al.
Published: (2025-07-01)

Diabetic Nephropathy: Proteinuria, Inflammation, and Fibrosis
by: Shirong Zheng, et al.
Published: (2016-01-01)

WCN25-2837 POST RENAL TRANSPLANT IMMUNOGLOBULIN A (IgA) NEPHROPATHY - NEED TO LOOK DEEPER !
by: RASHMI ALGERI, et al.
Published: (2025-02-01)

WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
by: Vivekanand Jha, et al.
Published: (2025-02-01)

Hydroxychloroquine sulfate for IgA nephropathy: mechanisms and therapeutic potential in improving proteinuria and alleviating disease progression - a literature review
by: Liao Yilei, et al.
Published: (2025-07-01)

The Prevalence and Characteristics of IgA Antibodies to β2-Spectrin and CBX3 in Immunoglobulin A Nephropathy
by: Ayako Koizumi, et al.
Published: (2025-05-01)

Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study
by: Yingman Guo, et al.
Published: (2024-12-01)

WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
by: Richard Lafayette, et al.
Published: (2024-04-01)

WCN25-932 STEROID (SYSTEMIC OR ENTERIC RELEASED BUDESONIDE) REFRACTORY NEPHROTIC RANGE PROTEINURIA IN IgA NEPHROPATHY; CAN TACROLIMUS BE AN ALTERNATIVE?- A CASE SERIES
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

Predictive value of serum IgG/C3 levels for membranous nephropathy in diabetics with proteinuria and negative phospholipase A2 receptor antibody
by: Huan Wang, et al.
Published: (2024-12-01)

WCN25-4378 OUTCOME OF USE OF ENTERIC RELEASED BUDESONIDE IN IgA NEPHROPATHY PATIENTS WITH NEPHROTIC AND SUBNEPHROTIC PROTEINURIA PRESENTATIONS: PROSPECTIVE COMPARATIVE STUDY IN TERTIARY CARE CENTRE
by: RAJA SINGHAL, et al.
Published: (2025-02-01)

WCN24-2269 MODERATE-SEVERE INTRARENAL ARTERIOSCLEROSIS AND CIRCULATING GDF-15 LEVELS MAY INFLUENCE THE CARDIAC-RENAL PROGNOSIS OF IgAN PATIENTS
by: Hong Cheng, et al.
Published: (2024-04-01)

Clinical study on leflunomide combined with valsartan in the treatment of diabetic nephropathy proteinuria
by: WANG Li, et al.
Published: (2017-01-01)